Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications.
In this study, we wanted to clarify the role of survivin-mediated survival signaling during G2 and M in tumor cells treated with DNA-damaging agents. As a cellular model, we selected MOLT-4 human T-cell lymphoblastic leukemia cells that overexpress survivin and nonfunctional p53. Treatment with melphalan, a classic DNA-damaging agent, led to the induction of the DNA damage checkpoint and growth arrest in the G2 phase of the cell cycle. Checkpoint abrogation by caffeine was accompanied by mitotic entry and rapid apoptotic cell death, whereas cells remaining in G2 remained viable during the same time interval. Unexpectedly, when the spindle checkpoint was activated following G2 abrogation, two different effects could be observed. If the microtubules of the melphalan-treated cells were destabilized by nocodazole, cells became arrested in prometaphase with low survivin levels and entered apoptosis. In contrast, if the microtubules of the melphalan-treated cells were stabilized by taxol, cells were still arrested in prometaphase, but apoptotic execution was inhibited. This effect is, most likely, directly mediated by survivin itself given its well-established antiapoptotic functions. In conclusion, depending on the way the spindle checkpoint was activated in cells with damaged DNA, cells could be either protected by survivin or die during mitosis. We suggest that the efficacy of DNA damage checkpoint abrogators used in combination with DNA-damaging agents may critically depend on whether DNA damage is able to invoke spindle checkpoint response and to activate survivin-associated survival signaling during mitosis.
Bozko
Przemyslaw
P
Laboratory of Molecular and Cellular Pharmacology, Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology, Narutowicza Street 11/12, 80-952 Gdansk, Poland.
Sabisz
Michal
M
Larsen
Annette K
AK
Skladanowski
Andrzej
A
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D015153:Blotting, Western; D002110:Caffeine / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival; D004249:DNA Damage; D053938:DNA Fragmentation; D016195:G2 Phase / Q000187:drug effects*; D006801:Humans; D008558:Melphalan / Q000494:pharmacology; D008938:Mitosis / Q000187:drug effects*; D015739:Nocodazole / Q000494:pharmacology; D017239:Paclitaxel / Q000494:pharmacology; D015398:Signal Transduction
D018906:Antineoplastic Agents, Alkylating; D002110:Caffeine; D017239:Paclitaxel; D008558:Melphalan; D015739:Nocodazole